Rationale and design of a randomized phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with epidermal growth factor receptor mutant non-squamous non-small-cell lung cancer: Study protocol

Chiyoe Kitagawa, Akiko Kada, Akiko M. Saito, Yukito Ichinose, Hideo Saka

研究成果: ジャーナルへの寄稿学術論文査読

2 被引用数 (Scopus)

抄録

Combination chemotherapy with platinum preparations is the standard first-line treatment for stage IIIB/IV non-small-cell lung cancer. However, the median survival in patients receiving this therapy is 8 to 10 months, and it is essential to improve the results of chemotherapy in non-small-cell lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors hinder EGFR signal transmission by binding to the adenosine triphosphate binding site of intracellular tyrosine kinase and inhibiting the autophospholylation of EGFR. They are a standard initial treatment option in EGFR gene mutation-positive patients. In Japan, gefitinib is routinely used. A combination of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and another antineoplastic drug may be a strategy to further improve treatment outcomes. We planned a randomized phase 2 trial to assess the efficacy and safety of gefitinib plus bevacizumab in such patients. In this study, subjects will be assigned to receive monotherapy with gefitinib (GEF group) or combination therapy with gefitinib and bevacizumab (GEF+BEV group) as the initial treatment at a ratio of 1:1. EGFR gene mutations are frequently detected in Asian patients with non-small-cell lung cancer.

本文言語英語
ページ(範囲)77-81
ページ数5
ジャーナルKurume Medical Journal
65
2
DOI
出版ステータス出版済み - 2018
外部発表はい

All Science Journal Classification (ASJC) codes

  • 医学一般

フィンガープリント

「Rationale and design of a randomized phase 2 trial of gefitinib plus bevacizumab vs gefitinib alone in patients with epidermal growth factor receptor mutant non-squamous non-small-cell lung cancer: Study protocol」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル